Loading...
Loading...
- Gilead Sciences Inc GILD reported Q2 sales of $6.26 billion, +1% Y/Y, beating the consensus of $5.86 billion, driven by increased sales of HIV and oncology products, partially offset by decreased sales of Veklury (remdesivir) and hepatitis C virus products.
- Q2 product sales were $6.1 billion, flat Y/Y and excluding Veklury, increased 7% to $5.7 billion.
- HIV product sales increased 7% to $4.2 billion, reflecting a higher average realized price and demand for treatment and pre-exposure prophylaxis medicines.
- Hepatitis C virus sales decreased 18% to $448 million.
- Cell therapy product sales increased 68% to $368 million.
- Veklury sales decreased by 46% to $445 million.
- Q2 adjusted EPS decreased 13% to $1.58, beating the consensus of $1.53.
- Dividend: Gilead declared a quarterly dividend of $0.73/share payable on September 29 for the record date of September 15.
- FY22 Outlook: Gilead forecasts FY22 product sales of $24.5 billion - $25 billion, compared to the previous guidance of $23.8 billion - $24.3 billion.
- The company expects Veklury sales of approximately $2.5 billion, compared to ~$2 billion expected earlier.
- It expects adjusted EPS of $6.35 - $6.75, up from $6.20 - $6.70 earlier guidance, and a consensus of $6.57.
- Price Action: GILD shares are up 1.97% at $60.71 during the pre-market session on Wednesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in